Skip to Content

Clinical Trials Search Results

Showing 1-10 of 39

Sorted By:

  • Acorn MDV3100-11

    A Phase 2, Single-Arm, Open-Label, Multicenter Study of the Clinical Activity and Safetyof Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple-Negative Breast Cancer

  • Alliance/NCCTG N0879

    A Randomized Phase II Trial of Carboplatin, Paclitaxel, Bevacizumab, with or without Everolimus for Therapy of Metastatic Malignant Melanoma.

  • Amgen 20070622

    A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG 102) With Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma

  • Astex AT13397-05

    A Study of HSP90 Inhibitor AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)

  • CALGB 50904

    A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib, and Bendamustine in Patients with Untreated Follicular Lymphoma

  • CALGB 80702

    A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer

  • CALGB 90601

    A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib, and Bendamustine in Patients with Untreated Follicular Lymphoma

  • CTSU E1Z11

    A Cohort Study of Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)

  • CTSU E5508

    A Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC.

  • CTSU ECOG E1609

    A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-risk Melanoma

Page of 4, showing trials 1-10 of 39

Also in this Section